Research and Development

Bayer’s blockbuster anticoagulant Xarelto is under scrutiny from regulators in Europe and the US, as they try to determine whether …

Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …

Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …

The European Medicines Agency’s (EMA) new executive director, Professor Guido Rasi, outlined his vision for his five-year mandate at the …

A pioneering trial is beginning in London, where doctors are harnessing patients’ own immune systems to find a new effective …

Novartis has reached a delivery milestone of 300 million paediatric antimalarial treatments, having supplied its Coartem dispersible without profit to …

It seems 2015 may be remembered as the year of the mega merger; the year when all records were broken …

The EMA has granted Gilead Sciences an accelerated assessment for its application for a new Sovaldi combination treatment.The combination contains …

Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …

Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with …

Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …

Featured Market Report: Forecast Report on Atopic Dermatitis (eczema) in 17 Major Markets  Black Swan’s report on Atopic Dermatitis, also …

Pfizer was extremely keen to get the $160 billion deal done, but what is it getting out of the acquisition, …

Merck and its development partner Threshold Pharmaceuticals say they will not pursue regulatory approval for evofosfamide in advanced soft tissue …

Takeda UK has announced post-treatment follow up data from the pivotal Phase II study of Adcetris revealing a five-year survival …